Live Q&A: Beneath the Surface: Moving Beyond Symptomatic Control in Obstructive Hypertrophic Cardiomyopathy

CMEO Webcast

Live Webcast: Wednesday, July 13, 2022
6:30 PM - 7:00 PM ET

This activity will offer CE credit for:

  1. Medicine (accme)
  2. Nursing (ANCC)
  3. Pharmacy (acpe)
  4. PA (aapa)

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Creditâ„¢

Credit Expiration Date: Thursday, July 13, 2023


Theodore Abraham, MD, FACC Theodore Abraham, MD, FACC (Moderator)
Meyer Friedman Distinguished Professor of Medicine
Co-Director, University of California at San Francisco
HCM Center of Excellence
San Francisco, CA

Steve R. Ommen, MD, FACC, FAHA Steve R. Ommen, MD, FACC, FAHA 
Professor of Medicine, Mayo Clinic
Director, Mayo Hypertrophic Cardiomyopathy Clinic
Rochester, MN

Carolyn Yung Ho, MD Carolyn Yung Ho, MD 
Medical Director, Cardiovascular Genetics Center
Cardiovascular Division, Brigham and Women's Hospital
Harvard Medical School
Boston, MA

Statement of Need

Hypertrophic cardiomyopathy (HCM) is the most common monogenic cardiac disease, with a highly variable phenotypic expression that ranges from no symptoms to drug-refractory heart failure. HCM is a lifelong condition that can worsen over time and is characterized by ventricular hypertrophy that cannot be explained by another cardiac or systemic disease. Patients may go years without a diagnosis despite being symptomatic, putting them at increased risk for atrial fibrillation, stroke, heart failure, and sudden cardiac death.

To provide the best quality of care and achieve optimal outcomes, it is critical for clinicians to properly screen appropriate patients and determine the etiology of symptoms, which are often non-specific. Genetic testing can help determine if the hypertrophy is associated with mutations in one of several sarcomeric genes which encode components of the contractile apparatus of the heart.

This live Q&A session is your opportunity to ask questions based on the CME Outfitters Live/Virtual/OnDemand symposium. Join Drs. Abraham, Ommen, and Ho to discuss the latest strategies and updates in HCM diagnosis and management, including progress with disease-specific treatments that target cardiac myosin. To view the full activity ahead of this live Q&A, Click Here.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Apply current, evidence-based diagnostic and treatment strategies to the care of patients with HCM.
  • Assess the chemomechanical cycle of cardiac myosin in HCM and the impact of myosin inhibition on disease factors.
  • Evaluate study results of disease-specific treatments targeting cardiac myosin in HCM.

Financial Support

Supported by an educational grant from Bristol Myers Squibb

Target Audience

Physicians, PAs, and nurse practitioners specializing in cardiology and electrophysiology

Credit Information

Specific CE Credit information is not available at this time. Please check again soon!

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Abraham reports no financial relationships.

Dr. Ommen reports no financial relationships.

Dr. Ho reports the following financial relationships:

Advisory Board: Bristol Myers Squibb

Consultant: Tenaya Therapeutics

Research: Pfizer Inc.

The following CME Outfitters staff report no financial relationships:
  • Warren Beckman (planning committee)
  • Evan Luberger (planning committee)
  • Susan H Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)

  • Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).

    This document was last modified on: